Analytical and clinical evaluation of the Bayer ADVIA Centaur® homocysteine assay

Clinica Chimica Acta

Volumn 342, Issue 1-2, 2004, Pages 171-178

  Tewari, Prakash C ^a   Zhang, Bin ^a   Bluestein, Barry I ^a  

^a BAYER CORPORATION   (United States)

Author keywords

Cardiovascular disease; Homocysteine; Immunoassay; Risk assessment

Indexed keywords

ANTIBODY; DISULFIDE; HOMOCYSTEINE; S ADENOSYLHOMOCYSTEINE;

ACCURACY; ADULT; AMINO ACID ANALYSIS; ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ANTIBODY LABELING; ARTICLE; AUTOANALYZER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOLUMINESCENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DILUTION; ENZYMATIC ASSAY; EPIDEMIOLOGICAL DATA; FEMALE; FLUORESCENCE ANALYSIS; FLUORESCENT POLARIZATION IMMUNOASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LINEAR REGRESSION ANALYSIS; LINEAR SYSTEM; MAGNETISM; MALE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REDUCTION; RISK ASSESSMENT;

ADOLESCENT; ADULT; AUTOANALYSIS; CHEMILUMINESCENT MEASUREMENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HOMOCYSTEINE; HUMANS; IMMUNOASSAY; LINEAR MODELS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 1542499806     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2003.12.025     Document Type: Article

References (20)

1. Centers for Disease Control and Prevention Heart disease and stroke: the nation's leading killers, a CDC report. 2003;Centers for Disease Control and Prevention, Atlanta, GA. (Source: www.cdc.gov/nccdphp/aag/aag_cvd.htm ).
2. Arnesen E., Refsum H., Bonaa K.H., Ueland P.M., Forde O.H., Nordrehaug J.E. Serum total homocysteine and coronary heart disease. Int. J. Epidemiol. 24:1995;704-709.
3. Graham I.M., Dale L.E., Refsum H.M., Robinson K., Brattstrom L.E., Ueland P.M.et al. Plasma homocysteine as a risk factor for vascular disease. The European concerted action project. JAMA. 277:1997;1775-1781.
4. Clarke R., Stansbie D. Assessment of homocysteine as a cardiovascular risk factor in clinical practice. Ann. Clin. Biochem. 38:2001;624-632.
5. He K., Merchant A., Rimm E.B., Rosner B.A., Stampfer M.J., Willett W.C. et al. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke. 35:2004;169-174.
6. Refsum H., Ueland P.M., Nygard O., Vollset S.E. Homocysteine and cardiovascular disease. Annu. Rev. Med. 48:1998;31-62.
7. Alpert M.A. Homocyst(e)ine, atherosclerosis, and thrombosis. South. Med. J. 92(9):1999;858-865.
8. McCully K.S. Vascular pathology of homocysteinemia: implication for the pathogenesis of arteriosclerosis. Am. J. Pathol. 56:1969;111-128.
9. Verhoef P., Kok F.J., Kruyssen D.A.C.M.et al. Plasma total homocysteine, B vitamins and risk of coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;989-995.
10. Malinow M.R., Bostom A.G., Krauss R.M. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the nutrition committee, American Heart Association. Circulation. 99:1999;178-182.
11. Nygård O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 337:1997;230-237.
12. Konecky N., Malinow M.R., Tunick P.A.et al. Correlation between plasma homocyst(e)ine and aortic atherosclerosis. Am. Heart J. 133:1997;534-540.
13. Wang H., Yoshizumi M., Lai K.et al. Inhibition of growth had p21 methylation in vascular endothelial cells by homocysteine but not cysteine. J. Biol. Chem. 272(40):1997;25380-25385.
14. Langman L.J., Cole D.E.C. Homocysteine: cholesterol of the 90s? Clin. Chim. Acta. 286:1999;63-80.
15. Grotjan H.E., Keel B.A. Data interpretation and quality control. Diamandis E.P., Christopoulos T.K. Immunoassay. 1996;51-62 Academic Press, New York.
16. Selhub J., Jacques P.F., Bostom A.G.et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N. Engl. J. Med. 332(5):1995;286-291.
17. Wollesen F., Brattstrom L., Refsum H., Ueland P.M., Berglund L., Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int. 55:1999;1028-1035.
18. Rasmussen K., Moller J., Lyngbak M., Pedersen A.M., Dybkjaer L. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clin. Chem. 42:1996;630-636.
19. Fokkema M.R., Weijer J.M., Dijck-Brouwer D.A.J., van Doormaal J.J., Muskiet F.A.J. Influence of vitamin-optimized plasma homocysteine cutoff values on the prevalence of hyperhomocysteinemia in healthy adults. Clin. Chem. 47:2001;1001-1007.
20. Cotton F., Wautrecht J.-C., Léchevin V.et al. Reference intervals for plasma homocysteine by the AxSYM Immunoassay after collection in fluoride Tubes. Clin. Chem. 49:2003;315-317.